IMB-203: For the Treatment of Inborn Errors of Metabolism

IMB-203 is a succinate prodrug i.e., a pharmacologically inactive compound that is metabolized into an active form within the body, for the treatment of inborn errors of metabolism. It is designed to deliver high quantities of succinate in patients in order to replenish succinate stores necessary for proper energy metabolism.

There are presently no approved therapies to deliver oral succinate.

In preclinical studies, IMB-203 was readily absorbed after oral administration and was found widely distributed in tissues throughout the body within one hour. After 24 hours, the majority of IMB-203 had been converted to CO2 and expelled by respiration from the body, consistent with metabolism in the tricarboxylic acid (TCA) cycle.